NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, Price Target & More

$4.88 +0.02 (+0.41 %)
(As of 04/19/2018 03:24 PM ET)
Previous Close$4.86
Today's Range$4.76 - $4.91
52-Week Range$3.92 - $8.38
Volume452,319 shs
Average Volume1.24 million shs
Market Capitalization$575.62 million
P/E Ratio-5.50
Dividend YieldN/A
Beta2.61

About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:KERX
CUSIP49251510
Phone617-466-3500

Debt

Debt-to-Equity Ratio-8.87%
Current Ratio3.12%
Quick Ratio2.49%

Price-To-Earnings

Trailing P/E Ratio-5.50
Forward P/E Ratio-8.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$60.64 million
Price / Sales9.59
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-40.67

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-163,440,000.00
Net Margins-269.52%
Return on Equity-10,954.62%
Return on Assets-62.33%

Miscellaneous

Employees210
Outstanding Shares119,180,000

How to Become a New Pot Stock Millionaire

Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced its quarterly earnings results on Wednesday, February, 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.08. The biopharmaceutical company earned $18.70 million during the quarter, compared to the consensus estimate of $17.53 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 269.52%. The business's revenue for the quarter was up 96.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.32) EPS. View Keryx Biopharmaceuticals' Earnings History.

When is Keryx Biopharmaceuticals' next earnings date?

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Keryx Biopharmaceuticals.

What price target have analysts set for KERX?

4 analysts have issued twelve-month target prices for Keryx Biopharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Keryx Biopharmaceuticals' share price to reach $6.6667 in the next year. View Analyst Ratings for Keryx Biopharmaceuticals.

What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Auryxia posted a good performance in 2017.  The FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential. However, with Auryxia being the only approved product in Keryx’s portfolio, the company is completely dependent on it for growth. Meanwhile, Auryxia faces stiff competition in the United States from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Also, Keryx may face strong pricing pressure for Auryxia. The company did not provide any guidance for 2018 as the company waits to see how Auryxia is adopted by the patients in the IDA setting. Consequently, shares of the company underperformed the industry." (4/11/2018)
  • 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:
  • Mr. Gregory P. Madison, CEO, Pres & Director (Age 50)
  • Mr. Scott A. Holmes, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
  • Mr. Brian R. Adams, Sr. VP, Gen. Counsel & Sec. (Age 44)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)

Has Keryx Biopharmaceuticals been receiving favorable news coverage?

Media headlines about KERX stock have been trending somewhat positive on Thursday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a news impact score of 0.23 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Keryx Biopharmaceuticals?

Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $4.88.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $575.62 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Keryx Biopharmaceuticals employs 210 workers across the globe.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]


MarketBeat Community Rating for Keryx Biopharmaceuticals (KERX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  657
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Keryx Biopharmaceuticals (NASDAQ:KERX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Keryx Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 36.61%. The high price target for KERX is $9.00 and the low price target for KERX is $5.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.252.252.20
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.6667$6.6667$7.00$7.50
Price Target Upside: 36.61% upside56.49% upside42.56% upside0.94% upside

Keryx Biopharmaceuticals (NASDAQ:KERX) Consensus Price Target History

Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals (NASDAQ:KERX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$7.00 -> $6.00LowView Rating Details
11/8/2017Stifel NicolausLower Price TargetHold$7.00 -> $5.00N/AView Rating Details
7/27/2017Maxim GroupSet Price TargetBuy$9.00HighView Rating Details
7/25/2017CowenReiterated RatingMarket PerformMediumView Rating Details
1/11/2017CitigroupUpgradeSell -> Neutral$7.00N/AView Rating Details
11/19/2016FBR & CoReiterated RatingHoldN/AView Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformN/AView Rating Details
8/2/2016Raymond JamesBoost Price TargetOutperform$7.00 -> $10.00N/AView Rating Details
8/2/2016Ladenburg ThalmannBoost Price TargetBuy$9.00 -> $10.00N/AView Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Keryx Biopharmaceuticals (NASDAQ:KERX) Earnings History and Estimates Chart

Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals (NASDAQ:KERX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS

Keryx Biopharmaceuticals (NASDAQ KERX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.17)N/AView Earnings Details
2/7/2018Q4 2017($0.18)($0.26)$17.53 million$18.70 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.17)($0.20)$18.88 million$15.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.17)($0.77)$14.51 million$15.10 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.18)($0.21)$10.19 million$11.82 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.25)($0.3190)$9.65 million$9.53 millionViewListenView Earnings Details
11/9/2016Q316($0.22)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015Q3 2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.70 million$0.57 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.39 million$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.23)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.10)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.12)($0.15)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
4/29/2011Q1 2011($0.08)($0.10)ViewN/AView Earnings Details
3/8/2011Q4 2010($0.07)($0.09)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.10)($0.10)ViewN/AView Earnings Details
8/8/2010Q2 2010($0.09)($0.09)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.07)($0.07)ViewN/AView Earnings Details
3/24/2010Q4 2009($0.06)($0.08)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.09)$0.01ViewN/AView Earnings Details
8/5/2009Q2 2009($0.07)$0.29ViewN/AView Earnings Details
5/13/2009Q1 2009($0.08)$0.01ViewN/AView Earnings Details
3/12/2009Q4 2008($0.14)($0.08)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.13)($0.15)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.20)($0.18)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.55)($0.57)ViewN/AView Earnings Details
2/22/2008Q4 2007($0.47)($0.67)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Keryx Biopharmaceuticals (NASDAQ:KERX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Keryx Biopharmaceuticals (NASDAQ KERX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.58%
Institutional Ownership Percentage: 65.42%
Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals (NASDAQ KERX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Brian AdamsGeneral CounselSell5,652$4.81$27,186.12View SEC Filing  
2/15/2018Greg MadisonInsiderSell15,318$4.81$73,679.58View SEC Filing  
2/15/2018Scott A HolmesCFOSell5,651$4.81$27,181.31View SEC Filing  
1/29/2018Brian AdamsGeneral CounselSell1,541$4.81$7,412.21View SEC Filing  
1/29/2018Scott A. HolmesCFOSell2,830$4.81$13,612.30View SEC Filing  
1/23/2018John F. NeylanInsiderSell1,322$4.92$6,504.24View SEC Filing  
1/18/2018Christine A. CarberryCOOSell9,048$4.87$44,063.76View SEC Filing  
1/5/2018Brian AdamsGeneral CounselSell753$4.69$3,531.57View SEC Filing  
1/5/2018Greg MadisonCEOSell1,067$4.69$5,004.23View SEC Filing  
10/30/2017Brian AdamsGeneral CounselSell1,405$6.03$8,472.15View SEC Filing  
10/30/2017Greg MadisonInsiderSell4,055$6.03$24,451.65View SEC Filing  
10/30/2017Scott A. HolmesCFOSell2,582$6.03$15,569.46View SEC Filing  
10/23/2017John F. NeylanInsiderSell1,179$6.53$7,698.87View SEC Filing  
10/5/2017Brian AdamsGeneral CounselSell630$7.19$4,529.70View SEC Filing  
10/5/2017Greg MadisonInsiderSell895$7.19$6,435.05View SEC Filing  
7/31/2017John F. NeylanInsiderSell1,445$7.14$10,317.30View SEC Filing  
7/28/2017Scott A. HolmesCFOSell1,236$6.96$8,602.56View SEC Filing  
7/24/2017John F. NeylanInsiderSell1,214$7.27$8,825.78View SEC Filing  
7/5/2017Brian AdamsGeneral CounselSell641$7.67$4,916.47View SEC Filing  
7/5/2017Greg MadisonInsiderSell910$7.67$6,979.70View SEC Filing  
4/28/2017Scott A. HolmesCFOSell1,219$5.89$7,179.91View SEC Filing  
4/24/2017John F. NeylanInsiderSell1,209$5.73$6,927.57View SEC Filing  
4/17/2017Brian AdamsGeneral CounselSell1,090$5.75$6,267.50View SEC Filing  
4/5/2017Brian AdamsGeneral CounselSell642$5.80$3,723.60View SEC Filing  
4/5/2017Greg MadisonInsiderSell911$5.80$5,283.80View SEC Filing  
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66259,681View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.8693,984View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00105,063View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50106,123View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00261,554View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.6053,132View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.6454,454View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63110,820View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.0059,742View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.1157,458View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.0054,742View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02302,330View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36878,603View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62304,417View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13492,861View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49880,419View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00476,429View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75555,929View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25459,065View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Keryx Biopharmaceuticals (NASDAQ KERX) News Headlines

Source:
DateHeadline
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA CongressKeryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
finance.yahoo.com - April 19 at 9:22 AM
Keryx Biopharmaceuticals (KERX) Upgraded to Buy by Zacks Investment ResearchKeryx Biopharmaceuticals (KERX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM
Keryx Biopharmaceuticals (KERX) Cut to "Buy" at BidaskClubKeryx Biopharmaceuticals (KERX) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 17 at 1:54 PM
BidaskClub Downgrades Keryx Biopharmaceuticals (KERX) to HoldBidaskClub Downgrades Keryx Biopharmaceuticals (KERX) to Hold
www.americanbankingnews.com - April 16 at 9:16 AM
Keryx Biopharmaceuticals (KERX) Given a $9.00 Price Target by Maxim Group AnalystsKeryx Biopharmaceuticals (KERX) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 15 at 4:33 PM
Keryx Biopharmaceuticals (KERX) Upgraded to Hold at ValuEngineKeryx Biopharmaceuticals (KERX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
Keryx Biopharmaceuticals (KERX) Receives Consensus Rating of "Hold" from BrokeragesKeryx Biopharmaceuticals (KERX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 7:41 PM
Keryx Biopharmaceuticals (KERX) Downgraded by BidaskClubKeryx Biopharmaceuticals (KERX) Downgraded by BidaskClub
www.americanbankingnews.com - April 12 at 6:15 PM
Today’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay TherapeuticsToday’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics
finance.yahoo.com - April 12 at 9:52 AM
Keryx Biopharmaceuticals (KERX) Upgraded to Sell by BidaskClubKeryx Biopharmaceuticals (KERX) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Zacks Investment Research Upgrades Keryx Biopharmaceuticals (KERX) to "Hold"Zacks Investment Research Upgrades Keryx Biopharmaceuticals (KERX) to "Hold"
www.americanbankingnews.com - April 11 at 9:52 AM
Keryx Biopharmaceuticals (KERX) Raised to Hold at Zacks Investment ResearchKeryx Biopharmaceuticals (KERX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:13 AM
Keryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $21.12 MillionKeryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $21.12 Million
www.americanbankingnews.com - April 5 at 3:58 AM
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of HematologyKeryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
finance.yahoo.com - April 4 at 9:14 AM
Keryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per ShareKeryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 3 at 11:14 AM
Stifel Nicolaus Lowers Keryx Biopharmaceuticals (KERX) Price Target to $5.00Stifel Nicolaus Lowers Keryx Biopharmaceuticals (KERX) Price Target to $5.00
www.americanbankingnews.com - April 1 at 9:46 AM
Keryx Biopharmaceuticals (KERX) Downgraded by BidaskClub to Strong SellKeryx Biopharmaceuticals (KERX) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - March 24 at 12:28 PM
Keryx Biopharmaceuticals (KERX) Cut to Strong Sell at BidaskClubKeryx Biopharmaceuticals (KERX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:48 AM
 Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $21.12 Million Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $21.12 Million
www.americanbankingnews.com - March 19 at 5:52 AM
Keryx Biopharmaceuticals (KERX) Given Average Rating of "Hold" by BrokeragesKeryx Biopharmaceuticals (KERX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 7:42 PM
-$0.19 Earnings Per Share Expected for Keryx Biopharmaceuticals (KERX) This Quarter-$0.19 Earnings Per Share Expected for Keryx Biopharmaceuticals (KERX) This Quarter
www.americanbankingnews.com - March 17 at 10:06 AM
Short Interest in Keryx Biopharmaceuticals (KERX) Drops By 8.4%Short Interest in Keryx Biopharmaceuticals (KERX) Drops By 8.4%
www.americanbankingnews.com - March 12 at 1:24 AM
Abrams Capital Management L.P. Has $45.19 Million Position in Keryx Biopharmaceuticals (KERX)Abrams Capital Management L.P. Has $45.19 Million Position in Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - March 6 at 4:13 AM
Options Traders Expect Huge Moves in Keryx (KERX) StockOptions Traders Expect Huge Moves in Keryx (KERX) Stock
finance.yahoo.com - March 5 at 10:03 AM
Reviewing Sierra Oncology (SRRA) and Keryx Biopharmaceuticals (KERX)Reviewing Sierra Oncology (SRRA) and Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - March 4 at 11:06 PM
 Analysts Expect Keryx Biopharmaceuticals (KERX) to Post -$0.19 EPS Analysts Expect Keryx Biopharmaceuticals (KERX) to Post -$0.19 EPS
www.americanbankingnews.com - February 28 at 9:22 AM
Keryx Biopharmaceuticals (KERX) & Seres Therapeutics (MCRB) Head-To-Head ReviewKeryx Biopharmaceuticals (KERX) & Seres Therapeutics (MCRB) Head-To-Head Review
www.americanbankingnews.com - February 26 at 3:06 AM
Keryx Biopharmaceuticals (KERX) Downgraded by ValuEngine to "Strong Sell"Keryx Biopharmaceuticals (KERX) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - February 25 at 6:35 PM
Keryx Biopharmaceuticals (KERX) Upgraded by BidaskClub to "Sell"Keryx Biopharmaceuticals (KERX) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 24 at 4:30 PM
Keryx Biopharmaceuticals Inc (KERX) Files 10-K for the Fiscal Year Ended on December 31, 2017Keryx Biopharmaceuticals Inc (KERX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 22 at 9:00 AM
Keryx Biopharmaceuticals (KERX) Given Consensus Recommendation of "Hold" by AnalystsKeryx Biopharmaceuticals (KERX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 21 at 7:30 PM
Keryx Biopharmaceuticals (KERX) CFO Scott A. Holmes Sells 5,651 SharesKeryx Biopharmaceuticals (KERX) CFO Scott A. Holmes Sells 5,651 Shares
www.americanbankingnews.com - February 16 at 10:20 PM
Insider Selling: Keryx Biopharmaceuticals (KERX) General Counsel Sells 5,652 Shares of StockInsider Selling: Keryx Biopharmaceuticals (KERX) General Counsel Sells 5,652 Shares of Stock
www.americanbankingnews.com - February 16 at 10:20 PM
Keryx Biopharmaceuticals (KERX) Insider Greg Madison Sells 15,318 SharesKeryx Biopharmaceuticals (KERX) Insider Greg Madison Sells 15,318 Shares
www.americanbankingnews.com - February 16 at 10:20 PM
Is the Options Market Predicting a Spike in Keryx (KERX) Stock?Is the Options Market Predicting a Spike in Keryx (KERX) Stock?
finance.yahoo.com - February 13 at 3:25 PM
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down - NasdaqKeryx (KERX) Loss Wider Than Expected in Q4, Stock Down - Nasdaq
www.nasdaq.com - February 9 at 6:46 AM
Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% SensitiveEarnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive
www.nasdaq.com - February 8 at 3:25 PM
Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% SensitiveEarnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive
www.nasdaq.com - February 8 at 3:25 PM
Keryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares DownKeryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares Down
finance.yahoo.com - February 8 at 3:25 PM
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial ResultsKeryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 8 at 3:25 PM
Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive - NasdaqEarnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive - Nasdaq
www.nasdaq.com - February 8 at 6:36 AM
Keryx Biopharmaceuticals (KERX) CEO Gregory Madison on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaKeryx Biopharmaceuticals' (KERX) CEO Gregory Madison on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 8 at 6:36 AM
Keryx Biopharmaceuticals (KERX) Posts  Earnings Results, Misses Expectations By $0.08 EPSKeryx Biopharmaceuticals (KERX) Posts Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - February 7 at 11:12 AM
Keryx (KERX) Warming Up to Q4 Earnings: Whats in Store?Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
www.zacks.com - February 7 at 6:43 AM
Keryx (KERX) Warming Up to Q4 Earnings: Whats in Store? - NasdaqKeryx (KERX) Warming Up to Q4 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - February 6 at 6:33 AM
Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
finance.yahoo.com - February 5 at 3:24 PM
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on ... - GlobeNewswire (press release)Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on ... - GlobeNewswire (press release)
globenewswire.com - February 4 at 6:40 AM
Keryx Biopharmaceuticals (KERX) Set to Announce Quarterly Earnings on WednesdayKeryx Biopharmaceuticals (KERX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 3 at 8:12 PM
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018
finance.yahoo.com - February 3 at 6:40 AM
Keryx Biopharmaceuticals (KERX) CFO Sells $13,612.30 in StockKeryx Biopharmaceuticals (KERX) CFO Sells $13,612.30 in Stock
www.americanbankingnews.com - January 31 at 6:56 PM

SEC Filings

Keryx Biopharmaceuticals (NASDAQ:KERX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Keryx Biopharmaceuticals (NASDAQ:KERX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Keryx Biopharmaceuticals (NASDAQ KERX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.